In last trading session, Syros Pharmaceuticals Inc (NASDAQ:SYRS) saw 0.57 million shares changing hands with its beta currently measuring 1.29. Company’s recent per share price level of $0.17 trading at -$0.01 or -0.85% at ring of the bell on the day assigns it a market valuation of $4.68M. That closing price of SYRS’s stock is at a discount of -4582.35% from its 52-week high price of $7.96 and is indicating a premium of 5.88% from its 52-week low price of $0.16.
For Syros Pharmaceuticals Inc (SYRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.75 in the current quarter.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Upright in the red during last session for losing -0.85%, in the last five days SYRS remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $0.17 price level, adding 14.91% to its value on the day. Syros Pharmaceuticals Inc’s shares saw a change of -24.15% in year-to-date performance and have moved -4.60% in past 5-day. Syros Pharmaceuticals Inc (NASDAQ:SYRS) showed a performance of -15.18% in past 30-days.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 96.6% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -2841.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -2841.18% for stock’s current value.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.16% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 72.84% while estimates for its earnings growth in next 5 years are of 26.35%.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 654.18 shares of worth $0.11 million or 2.44% of the total outstanding shares. The later fund manager was in possession of 257.63 shares on Sep 30, 2024 , making its stake of worth around $44905.0 in the company or a holder of 0.96% of company’s stock.
